The U.S. Food and Drug Administration (FDA) has submitted a proposed interim policy to the White House that could make it easier for compounding pharmacies to prepare certain peptides. The FDA peptide compounding policy change could affect access to substances such as BPC-157, a peptide promoted for muscle recovery and other wellness uses. However, the proposal remains under review, and its final terms have not been publicly detailed.
Reuters reported on October 15, 2026, that the FDA and the Department of Health and Human Services (HHS) had submitted an “interim access policy for compounding using certain peptides” for White House consideration. The move follows an FDA advisory committee review of several peptides in July.
What Is Proposed For FDA Peptide Compounding Policy Change?
The proposed FDA peptide compounding policy change could allow pharmacies to compound certain peptides under temporary enforcement discretion. This means the agency may choose not to take specified enforcement action under defined conditions. It does not change the underlying law or establish that a drug is safe and effective.
Peptides are short chains of amino acids, the building blocks of proteins. Some peptide-based medicines have established medical uses, while others promoted for recovery, anti-aging, and wellness lack sufficient evidence to establish their benefits and risks.
The FDA advisers recommended easing restrictions on six of the seven peptides reviewed in July 2026, including BPC-157. However, an advisory committee recommendation is not a final regulatory decision.
The White House policy review will help determine the next steps. The public filing does not specify which substances will qualify, when a policy might take effect, or what conditions pharmacies would need to meet.
What Could Change for Compounding Pharmacies and Telehealth?
Compounding pharmacies prepare medications by combining or adjusting ingredients to meet specific needs. Federal rules restrict which bulk drug substances pharmacies can use and under what circumstances.
If the FDA peptide compounding policy change goes forward, eligible pharmacies could gain a temporary route to compound certain peptides that face existing restrictions. The practical impact will depend on the final policy, including its eligible substances and operating conditions.
Telehealth companies may also benefit if peptide compounding regulations permit new prescribing and dispensing services. Hims & Hers Health has previously expressed interest in offering peptides if regulations allow it.
However, businesses must not treat the proposal as permission to begin offering every previously restricted peptide. Pharmacies and telehealth providers will need to confirm the applicable federal and state requirements before launching services or advertising availability.
What Are The Concerns About Unapproved Peptides?
Patient safety remains a central issue in the debate over peptide compounding regulations. BPC-157 is promoted online for injury recovery and other benefits, but evidence from well-controlled human studies remains limited.
The FDA has identified concerns involving BPC-157 safety and other substances, including potential immune reactions, peptide-related impurities, and inadequate human safety information. These uncertainties make it difficult to establish whether certain formulations are safe for human use.
Compounded drugs do not undergo the same FDA premarket review for safety, effectiveness, and quality as approved medicines. Easier access therefore would not establish that a peptide works as advertised or is appropriate for a particular patient.
Patients should discuss treatment options with qualified healthcare professionals and be cautious about claims based mainly on social media testimonials or anecdotal experiences.
What Happens Next With the FDA Peptide Policy?
The proposed FDA peptide compounding policy change must progress through White House review before its final status and conditions become clear. The FDA has not publicly disclosed the complete terms in the filing, according to reports.
The changes in FDA peptide restrictions could reshape access to certain compounded peptides, but their impact will depend on the final policy and the safety requirements that accompany it. Until those details are confirmed, regulatory uncertainty and questions about clinical evidence remain central to the debate.
